Corbus Pharmaceuticals Holdings (CRBP) Current Deferred Revenue (2015 - 2020)

Corbus Pharmaceuticals Holdings has reported Current Deferred Revenue for 6 years, with the latest figure at $270530.0 in Q2 2020.

• On a quarterly basis, Current Deferred Revenue fell 89.1% year-over-year to $270530.0 in Q2 2020; TTM through Jun 2020 was $270530.0, a 89.1% decrease from a year earlier, with the FY2018 full-year figure at $1.5 million, changed N/A from the prior year.
• Current Deferred Revenue was $270530.0 for Q2 2020 at Corbus Pharmaceuticals Holdings, down from $2.5 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $27.0 million in Q1 2019, with the low at $270530.0 in Q2 2020.
• Average Current Deferred Revenue over 5 years is $3.8 million, with a median of $1.5 million recorded in 2016.
• The sharpest annual moves came in 2018 and 2020: Current Deferred Revenue jumped 1412.16% in 2018, then sank 89.1% in 2020.
• Over 5 years, Current Deferred Revenue stood at $1.9 million in 2016, then plunged by 84.73% to $296311.0 in 2017, then surged by 393.57% to $1.5 million in 2018, then soared by 69.73% to $2.5 million in 2019, then tumbled by 89.1% to $270530.0 in 2020.
• The last three Current Deferred Revenue figures came in at $270530.0 (Q2 2020), $2.5 million (Q2 2019), and $27.0 million (Q1 2019), per Business Quant data.